+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bioequivalence Studies Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Dosage Form, By Therapeutic Area, By Region, And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 175 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 5846840
Description Jump to:
The global bioequivalence studies market size is expected to reach USD 1,272.2 million by 2030, expanding at a CAGR of 8.3% from 2023 to 2030, according to this report. The increasing R&D activities pertaining to rare diseases and growing demand for generics are the key factors driving the growth of the market for bioequivalence studies.

Bioequivalence studies are used to analyze the desired in vivo biological equivalence of two formulations of drug products. If two drugs are bioequivalent, then they would be anticipated to reflect equal rates of bioavailability and pharmacokinetic (PK) parameters for all intents and purposes. Some of the major players in the market include ProRelix Services LLP, IQVIA, ICON plc, Charles River Laboratories, and Labcorp Drug Development, among others.

These companies offer a wide range of bioequivalence and bioavailability services to research institutes, pharmaceutical companies, and government agencies involved in drug development. In addition, the increasing pace of clinical research activities with an aim to develop low-cost biosimilars and generics across disease areas such as cancer, neurology, immunology, etc., is anticipated to boost the market growth for bioequivalence studies.

The growing rate of generics launches has helped to create a significant demand for bioequivalence studies over the past few years. For instance, the U.S. Food and Drug Administration (FDA) announced that as of January 2022, there are 33 FDA-approved biosimilars in the U.S., among which 21 are commercially available in the market.

The COVID-19 pandemic negatively impacted the market for bioequivalence studies. However, several players adopted inorganic strategies to mitigate this situation and rebound their sales figures. Additionally, the geopolitical war between Russia and Ukraine has led to a drop in revenue across the bioequivalence industry, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain economies, such as the U.S., due to which the overall market witnessed a moderate dip in its revenue during 2022.

Bioequivalence Studies Market Report Highlights

  • The small molecule segment accounted for the largest revenue share of 60.6% in 2022.The segment is driven by the steadily growing demand for generics, which constitute a vast portion of small molecules
  • Based on the dosage form, the solid oral dosage segment accounted for the largest revenue share of 53.8% in 2022, owing to innovations in the technology involved in manufacturing oral solids at an optimal quality
  • The oncology segment is anticipated to register the fastest CAGR of 8.7% during the forecast period. This is due to the growing rate of anti-cancer biosimilars being approved in the market
  • Asia Pacific is anticipated to witness the highest CAGR of 8.8% during the forecast timeframe. The expected high growth is primarily since Asian countries such as India and China are major exporters of generic drugs, which also suggests that they have a stronghold in the production of generic drugs, thereby supporting demand for bioequivalence studies

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Bioequivalence Studies Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.3. Industry challenges
3.3. Bioequivalence Studies: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.4. Market Entry Strategies
3.3.5. COVID-19 Impact Analysis
Chapter 4. Bioequivalence Studies Market: Molecule Type Estimates & Trend Analysis
4.1. Bioequivalence Studies Market: Definition & Scope
4.2. Bioequivalence Studies Market: Molecule Type Market Share Analysis, 2022 & 2030
4.2.1. Small Molecule
4.2.1.1. Small Molecule Market estimates and forecast 2018 to 2030 (USD Million)
4.2.2. Large Molecule
4.2.2.1. Large Molecule Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Bioequivalence Studies Market: Dosage Form Estimates & Trend Analysis
5.1. Bioequivalence Studies Market: Definition & Scope
5.2. Bioequivalence Studies Market: Dosage Form Market Share Analysis, 2022 & 2030
5.2.1. Solid Oral Dosage
5.2.1.1. Solid Oral Dosage Market estimates and forecast 2018 to 2030 (USD Million)
5.2.2. Parenteral Formulations
5.2.2.1. Parenteral Formulations Market estimates and forecast 2018 to 2030 (USD Million)
5.2.3. Topical Products
5.2.3.1. Topical Products Market estimates and forecast 2018 to 2030 (USD Million)
5.2.4. Others
5.2.4.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Bioequivalence Studies Market: Therapeutic Area Estimates & Trend Analysis
6.1. Bioequivalence Studies Market: Definition & Scope
6.2. Bioequivalence Studies Market: Therapeutic Area Market Share Analysis, 2022 & 2030
6.2.1. Oncology
6.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
6.2.2. Neurology
6.2.2.1. Neurology Market estimates and forecast 2018 to 2030 (USD Million)
6.2.3. Metabolic Disorders
6.2.3.1. Metabolic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
6.2.4. Hematology
6.2.4.1. Hematology Market estimates and forecast 2018 to 2030 (USD Million)
6.2.5. Immunology
6.2.5.1. Immunology Market estimates and forecast 2018 to 2030 (USD Million)
6.2.6. Orthopedics
6.2.6.1. Orthopedics Market estimates and forecast 2018 to 2030 (USD Million)
6.2.7. Others
6.2.7.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Bioequivalence Studies Market: Phase Estimates & Trend Analysis
7.1. Bioequivalence Studies Market: Definition & Scope
7.2. Bioequivalence Studies Market: Phase Market Share Analysis, 2022 & 2030
7.2.1. Drug Discover
7.2.1.1. Drug Discover Market estimates and forecast 2018 to 2030 (USD Million)
7.2.2. Preclinical Studies
7.2.2.1. Preclinical Studies Market estimates and forecast 2018 to 2030 (USD Million)
7.2.3. Clinical Studies
7.2.3.1. Clinical Studies Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. Bioequivalence Studies Market: Regional Estimates & Trend Analysis
8.1. Regional market share analysis, 2022 & 2030
8.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. Market estimates and forecast, 2018 - 2030 (Value)
8.3.2. U.S.
8.3.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.3.3. Canada
8.3.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4. Europe
8.4.1. U.K.
8.4.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.2. Germany
8.4.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.3. France
8.4.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.4. Italy
8.4.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.5. Spain
8.4.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.6. Denmark
8.4.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.7. Sweden
8.4.7.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.4.8. Norway
8.4.8.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecast, 2018 - 2030 (USD Billion, Volume, Thousand)
8.5.2. China
8.5.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.5.3. India
8.5.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.5.4. Australia
8.5.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.5.5. Thailand
8.5.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.5.6. South Korea
8.5.6.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.6.2. Mexico
8.6.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.6.3. Argentina
8.6.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.7.2. Saudi Arabia
8.7.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.7.3. UAE
8.7.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
Chapter 9. Competitive Landscape
9.1. Company Market Share Analysis, 2022
9.2. Company Profiles
9.2.1. CliniExperts
9.2.1.1. Company overview
9.2.1.2. Financial Performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. ICBIO Corporation
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. ProRelix Services LLP
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. PPD, Inc
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Syneos Health
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Labcorp Drug Development
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. IQVIA
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Charles River Laboratories Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Icon PLC
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Intertek Group plc
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
List of Tables
Table 1: List of secondary sources
Table 2: List of Abbreviations
Table 3: North America Bioequivalence Studies market, by region, 2018-2030 (USD Million)
Table 4: North America Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 5: North America Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 6: North America Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 7: U.S. Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 8: U.S. Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 9: U.S. Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 10: Canada Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 11: Canada Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 12: Canada Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 13: Europe Bioequivalence Studies market, by region, 2018-2030 (USD Million)
Table 14: Europe Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 15: Europe Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 16: Europe Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 17: U.K. Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 18: U.K. Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 19: U.K. Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 20: Germany Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 21: Germany Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 22: Germany Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 23: France Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 24: France Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 25: France Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 26: Italy Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 27: Italy Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 28: Italy Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 29: Spain Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 30: Spain Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 31: Spain Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 32: Denmark Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 33: Denmark Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 34: Denmark Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 35: Sweden Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 36: Sweden Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 37: Sweden Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 38: Norway Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 39: Norway Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 40: Norway Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 41: Asia Pacific Bioequivalence Studies market, by region, 2018-2030 (USD Million)
Table 42: Asia Pacific Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 43: Asia Pacific Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 44: Asia Pacific Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 45: China Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 46: China Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 47: China Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 48: Japan Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 49: Japan Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 50: Japan Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 51: India Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 52: India Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 53: India Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 54: Australia Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 55: Australia Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 56: Australia Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 57: South Korea Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 58: South Korea Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 59: South Korea Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 60: Thailand Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 61: Thailand Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 62: Thailand Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 63: Latin America Bioequivalence Studies market, by region, 2018-2030 (USD Million)
Table 64: Latin America Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 65: Latin America Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 66: Latin America Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 67: Brazil Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 68: Brazil Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 69: Brazil Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 70: Mexico Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 71: Mexico Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 72: Mexico Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 73: Argentina Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 74: Argentina Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 75: Argentina Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 76: Middle East and Africa Bioequivalence Studies market, by region, 2018-2030 (USD Million)
Table 77: Middle East and Africa Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 78: Middle East and Africa Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 79: Middle East and Africa Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 80: South Africa Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 81: South Africa Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 82: South Africa Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 83: Saudi Arabia Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 84: Saudi Arabia Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 85: Saudi Arabia Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 86: UAE Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 87: UAE Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 88: UAE Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
Table 89: Kuwait Bioequivalence Studies market, by Dosage Form type, 2018-2030 (USD Million)
Table 90: Kuwait Bioequivalence Studies market, by Molecule Type, 2018-2030 (USD Million)
Table 91: Kuwait Bioequivalence Studies market, by Therapeutic Area, 2018-2030 (USD Million)
List of Figures
Fig. 1: Market research process
Fig. 2: Information procurement
Fig. 3: Market research approaches
Fig. 4: QFD modelling for market share assessment
Fig. 5: Market formulation & validation
Fig. 6: Commodity flow analysis
Fig. 7: Primary research pattern
Fig. 8: Primary interviews in North America
Fig. 9: Primary interviews in Europe
Fig. 10: Primary interviews in Asia Pacific
Fig. 11: Primary interviews in Latin America
Fig. 12: Primary interviews in MEA
Fig. 13: Market Snapshot
Fig. 14: Segment Snapshot
Fig. 15: Segment Snapshot
Fig. 16: Competitive Landscape Snapshot
Fig. 17: Bioequivalence Studies market segmentation
Fig. 18: Parent market outlook (2022)
Fig. 19: Related/ancillary market outlook (2022)
Fig. 20: Market driver relevance analysis (Current & future impact)
Fig. 21: Current shared services and outsourcing usage levels
Fig. 22: Market restraint relevance analysis (Current & future impact)
Fig. 23: Porter’s five forces analysis
Fig. 24: SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 25: Bioequivalence Studies Market Molecule Type outlook: Segment dashboard
Fig. 26: Bioequivalence Studies: Molecule Type movement analysis
Fig. 27: Small Molecule market, 2018-2030 (USD Million)
Fig. 28: Large Molecule market, 2018-2030 (USD Million)
Fig. 29: Bioequivalence Studies Market Dosage Form type outlook: Segment dashboard
Fig. 30: Bioequivalence Studies: Dosage Form movement analysis
Fig. 31: Solid Oral Dosage market, 2018-2030 (USD Million)
Fig. 32: Parenteral Formulations market, 2018-2030 (USD Million)
Fig. 33: Topical Products market, 2018-2030 (USD Million)
Fig. 34: Others market, 2018-2030 (USD Million)
Fig. 35: Bioequivalence Studies market Therapeutic Area outlook: Segment dashboard
Fig. 36: Bioequivalence Studies market: Therapeutic Area movement analysis
Fig. 37: Oncology market, 2018-2030 (USD Million)
Fig. 38: Neurology market, 2018-2030 (USD Million)
Fig. 39: Metabolic Disorders market, 2018-2030 (USD Million)
Fig. 40: Hematology market, 2018-2030 (USD Million)
Fig. 41: Immunology market, 2018-2030 (USD Million)
Fig. 42: Others market, 2018-2030 (USD Million)
Fig. 43: Regional marketplace: Segment dashboard
Fig. 44: Regional outlook, 2022 & 2030
Fig. 45: North America market, 2018-2030 (USD Million)
Fig. 46: U.S. market, 2018-2030 (USD Million)
Fig. 47: Canada market, 2018-2030 (USD Million)
Fig. 48: Europe market, 2018-2030 (USD Million)
Fig. 49: Germany market, 2018-2030 (USD Million)
Fig. 50: UK market, 2018-2030 (USD Million)
Fig. 51: France market, 2018-2030 (USD Million)
Fig. 52: Italy market, 2018-2030 (USD Million)
Fig. 53: Spain market, 2018-2030 (USD Million)
Fig. 54: Denmark market, 2018-2030(USD Million)
Fig. 55: Sweden market, 2018-2030 (USD Million)
Fig. 56: Norway market, 2018-2030 (USD Million)
Fig. 57: Asia Pacific market, 2018-2030 (USD Million)
Fig. 58: China market, 2018-2030 (USD Million)
Fig. 59: Japan market, 2018-2030 (USD Million)
Fig. 60: India market, 2018-2030 (USD Million)
Fig. 61: Australia market, 2018-2030 (USD Million)
Fig. 62: South Korea market, 2018-2030 (USD Million)
Fig. 63: Thailand market, 2018-2030 (USD Million)
Fig. 64: Latin America market, 2018-2030 (USD Million)
Fig. 65: Brazil market, 2018-2030 (USD Million)
Fig. 66: Mexico market, 2018-2030 (USD Million)
Fig. 67: Argentina market, 2018-2030 (USD Million)
Fig. 68: Middle East & Africa market, 2018-2030 (USD Million)
Fig. 69: South Africa market, 2018-2030 (USD Million)
Fig. 70: Saudi Arabia market, 2018-2030 (USD Million)
Fig. 71: UAE market, 2018-2030 (USD Million)
Fig. 72: Kuwait market, 2018-2030 (USD Million)

Companies Mentioned

  • CliniExperts
  • ICBIO Corporation
  • ProRelix Services LLP
  • PPD, Inc
  • Syneos Health
  • Labcorp Drug Development
  • IQVIA
  • Charles River Laboratories Inc.
  • Icon PLC
  • Intertek Group plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages175
PublishedJune 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 679.8 Million
Forecasted Market Value ( USD ) by 2030 $ 1272.2 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Pharmaceutical Dissolution Testing, Bioavailability, and Bioequivalence. Science, Applications, and Beyond. Edition No. 1 - Product Image

Pharmaceutical Dissolution Testing, Bioavailability, and Bioequivalence. Science, Applications, and Beyond. Edition No. 1

  • Book
  • 560 Pages
Pharmaceutical Quality by Design. Principles and Applications - Product Image

Pharmaceutical Quality by Design. Principles and Applications

  • Book
High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Innovative, Generic), Dosage Form (Injectable, Creams), Application, Synthesis, Region, and Segment Forecasts, 2025-2030 - Product Image

High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Innovative, Generic), Dosage Form (Injectable, Creams), Application, Synthesis, Region, and Segment Forecasts, 2025-2030

  • Report
  • 130 Pages
  • Global
From
Chemistry, Manufacturing And Control Services Outsourcing Market Size, Share & Trends Analysis Report By Type (API, Finished Drug Formulation, Medical Devices), By Service, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Chemistry, Manufacturing And Control Services Outsourcing Market Size, Share & Trends Analysis Report By Type (API, Finished Drug Formulation, Medical Devices), By Service, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 210 Pages
  • Global
From
Continuous Manufacturing of Pharmaceuticals. Edition No. 1. Advances in Pharmaceutical Technology - Product Image

Continuous Manufacturing of Pharmaceuticals. Edition No. 1. Advances in Pharmaceutical Technology

  • Book
  • 632 Pages

About the Bioequivalence Market

Bioequivalence is a term used in biotechnology to describe the similarity between two pharmaceutical products. It is used to assess the interchangeability of two products, such as generic and brand-name drugs, and to ensure that they have the same therapeutic effect. Bioequivalence studies are conducted to compare the pharmacokinetic properties of two products, such as their absorption, distribution, metabolism, and excretion. The results of these studies are used to determine whether the two products are therapeutically equivalent and can be used interchangeably. The bioequivalence market is a rapidly growing sector of the biotechnology industry. It is driven by the increasing demand for generic drugs, as well as the need for regulatory compliance. Companies in this market provide services such as bioequivalence studies, pharmacokinetic analysis, and regulatory consulting. Some companies in the bioequivalence market include Parexel, Covance, Quintiles, and PPD. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.